Differentiated thyroid cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up.

Differentiated thyroid cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up F. Pacini, M. G. Castagna, L. Brilli & G. Pentheroudakis On behalf of the ESMO Guidelines Working Group* Section of Endocrinology and Metabolism, Department of Internal Medicine, Endocrinology and Metabolism and Biochemistry, University of Siena, Siena, Italy; Department of Medical Oncology, Ioannina University Hospital, Ioannina, Greece

[1]  Xu Xi,et al.  To Be American , 2011, Fourth Genre: Explorations in Nonfiction.

[2]  Stephanie L. Lee,et al.  Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. , 2009, Thyroid : official journal of the American Thyroid Association.

[3]  A. Jemal,et al.  Cancer Statistics, 2008 , 2008, CA: a cancer journal for clinicians.

[4]  M. Ferdeghini,et al.  Clinical relevance of highly sensitive Tg assay in monitoring patients treated for differentiated thyroid cancer , 2007, Clinical endocrinology.

[5]  T. Pilli,et al.  A comparison of 1850 (50 mCi) and 3700 MBq (100 mCi) 131-iodine administered doses for recombinant thyrotropin-stimulated postoperative thyroid remnant ablation in differentiated thyroid cancer. , 2007, The Journal of clinical endocrinology and metabolism.

[6]  S. Koscielny,et al.  Comparison of seven serum thyroglobulin assays in the follow-up of papillary and follicular thyroid cancer patients. , 2007, The Journal of clinical endocrinology and metabolism.

[7]  Thomas J Lynch,et al.  A phase II study of gefitinib in patients with advanced thyroid cancer. , 2008, Thyroid : official journal of the American Thyroid Association.

[8]  L. Bastholt,et al.  Initial results from a phase II trial of motesanib diphosphate (AMG 706) in patients with differentiated thyroid cancer (DTC) , 2007 .

[9]  G. de Pouvourville,et al.  Recombinant Human Thyroid-Stimulating Hormone: Use in Papillary and Follicular Thyroid Cancer , 2007, Hormone Research in Paediatrics.

[10]  M. Stumvoll,et al.  Evaluation of Patients’ Opinion and Metabolic Control after Transfer of Young Adults with Type 1 Diabetes from a Pediatric Diabetes Clinic to Adult Care , 2006, Hormone Research in Paediatrics.

[11]  W. Wiersinga,et al.  European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. , 2006, European journal of endocrinology.

[12]  Louise Davies,et al.  Increasing incidence of thyroid cancer in the United States, 1973-2002. , 2006, JAMA.

[13]  Gerard M Doherty,et al.  Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. , 2006, Thyroid : official journal of the American Thyroid Association.

[14]  R. Wahl,et al.  Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: results of an international, randomized, controlled study. , 2006, The Journal of clinical endocrinology and metabolism.

[15]  B. Biondi,et al.  Thyroid-hormone therapy and thyroid cancer: a reassessment , 2005, Nature Clinical Practice Endocrinology &Metabolism.

[16]  F. Pacini,et al.  Management of thyroid nodules: a clinicopathological, evidence-based approach , 2004, European Journal of Nuclear Medicine and Molecular Imaging.

[17]  M. Schlumberger,et al.  Advances in diagnostic practices affect thyroid cancer incidence in France. , 2004, European journal of endocrinology.

[18]  C. Compton,et al.  TNM residual tumor classification revisited , 2002, Cancer.

[19]  A. Pinchera,et al.  Diagnostic 131-iodine whole-body scan may be avoided in thyroid cancer patients who have undetectable stimulated serum Tg levels after initial treatment. , 2002, The Journal of clinical endocrinology and metabolism.

[20]  C. la Vecchia,et al.  Thyroid cancer in Vaud, Switzerland: an update. , 2002, Thyroid.

[21]  E. Hovorková,et al.  Sensitivity and specificity of the fine needle aspiration biopsy of the thyroid: clinical point of view , 1999, Clinical endocrinology.

[22]  M. Schlumberger,et al.  Radioactive iodine treatment and external radiotherapy for lung and bone metastases from thyroid carcinoma. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[23]  S. Jhiang,et al.  Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. , 1994, The American journal of medicine.

[24]  F. Cetani,et al.  Outcome of 309 patients with metastatic differentiated thyroid carcinoma treated with radioiodine , 1994, World Journal of Surgery.

[25]  T. Pilli,et al.  Limited value of repeat recombinant human thyrotropin (rhTSH)-stimulated thyroglobulin testing in differentiated thyroid carcinoma patients with previous negative rhTSH-stimulated thyroglobulin and undetectable basal serum thyroglobulin levels. , 2008, The Journal of clinical endocrinology and metabolism.

[26]  T. P. Fox,et al.  Monitoring thyroglobulin in a sensitive immunoassay has comparable sensitivity to recombinant human tsh-stimulated thyroglobulin in follow-up of thyroid cancer patients. , 2007, The Journal of clinical endocrinology and metabolism.

[27]  E. Mazzaferri.  Increasing Incidence of Thyroid Cancer in the United States, 1973–2002Davies L, Welch HG (Dept of Veterans Affairs Med Ctr, White River Junction, Vt; Darmouth Med School, Hanover, NH) JAMA 295:2164–2167, 2006§ , 2007 .

[28]  E. Baudin,et al.  Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. , 2006, The Journal of clinical endocrinology and metabolism.

[29]  R. Kloos,et al.  A single recombinant human thyrotropin-stimulated serum thyroglobulin measurement predicts differentiated thyroid carcinoma metastases three to five years later. , 2005, The Journal of clinical endocrinology and metabolism.

[30]  A. Pinchera,et al.  Impact of routine measurement of serum calcitonin on the diagnosis and outcome of medullary thyroid cancer: experience in 10,864 patients with nodular thyroid disorders. , 2004, The Journal of clinical endocrinology and metabolism.

[31]  E. Baudin,et al.  Is diagnostic iodine-131 scanning useful after total thyroid ablation for differentiated thyroid cancer? , 2000, The Journal of clinical endocrinology and metabolism.